Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 9 of 14

6. Tiziana Life Sciences Ltd (NASDAQ:TLSA)

Number of Hedge Fund Holders In Q4 2024: N/A

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a biotech company that makes immunomodulation therapies. Its lead candidate is a fully human anti-CD3 monoclonal antibody for treating neurodegenerative and inflammatory diseases. It is called intranasal foralumab.

The stock is up significantly so far in 2025 due to the publication of a study in Nature Neuroscience showing positive results for nasal anti-CD3 therapy in traumatic brain injury.

Moreover, it announced that its Long COVID study using foralumab is nearing completion in Q2 2025.

It also announced a product development services agreement with Renaissance Lakewood. This is a contract development and manufacturing organization specializing in nasal drug delivery.

TLSA is up 62.31% year-to-date.

Page 9 of 14